SPI Pharma, a global developer of excipients, drug delivery technologies, vaccine adjuvants, and antacid actives, unveiled a new brand identity that reflects the company's evolution and its commitment to helping customers solve complex formulation challenges and improve the quality of people's lives.
The new identity introduces a refreshed visual system, a clearer brand voice, and the tagline "Let's solve it together." It is designed to reflect SPI Pharma's role as a trusted partner to pharmaceutical and nutraceutical companies, combining technical expertise, innovation, and collaboration to help bring better products to market.
The new brand will be introduced across SPI Pharma's digital channels, customer communications, and industry events, with packaging and other materials transitioning through normal update cycles. Product performance, quality systems, specifications, and regulatory documentation remain unchanged.
Freek Snieders, CEO of SPI Pharma, said, "This is more than a new look for SPI Pharma. It represents the next chapter in our evolution as a company and reflects our ambition for the future. As our customers navigate increasingly complex formulation challenges, we are focused on being more than a supplier. We aspire to be a trusted partner, bringing together scientific expertise, innovative solutions, and deep collaboration to help customers develop better products and improve the lives of patients around the world. Our new brand captures the energy, confidence, and forward momentum of SPI Pharma as we continue to grow alongside our customers."
SPI Pharma is headquartered in Wilmington, Delaware, and operates manufacturing, R&D, and commercial teams across the world. SPI Pharma is part of ABF Ingredients, a division of Associated British Foods plc. |